Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer. The company provides AVT02, a high concentration, low-volume adalimumab formulation biosimilar to H…
| Periodo | 2026-11 | 2026-08 | 2026-05 | 2026-03 |
|---|---|---|---|---|
| Real | — | — | $-0.09 | $0.01 |
| Estimado | $-0.04 | $-0.08 | $-0.07 | $-0.01 |
| Sorpresa | — | — | -28.6% | +200.0% |
| Métrica | ALVO | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | 59.8% | 57.4% | +2.4% |
| Operating Margin | 13.3% | -34.4% | +47.7% |
| Net Margin | 4.8% | -32.5% | +37.2% |
| FCF Margin | -19.6% | -12.6% | -7.0% |
| ROE | — | -39.2% | — |
| ROA | 1.9% | -30.9% | +32.8% |
| Current Ratio | 1.89 | 2.73 | -0.84 |
| Debt / Equity | -4.44 | 0.28 | -4.72 |
| Tendencia (Piotroski) | FY25 | FY24 |
|---|---|---|
| ✓Rentabilidad sobre activos positiva | 1.9% | — |
| ✗Flujo de caja operativo positivo | −$50M | −$237M |
| ✓Rentabilidad sobre activos al alza | 1.9% | -19.0% |
| ✗Caja operativa/activos supera al ROA | -3.4% | ROA 1.9% |
| ✗Menos deuda a largo plazo | 84.9% | 84.8% |
| ✗Mejor liquidez (ratio corriente) | 1.89 | 2.35 |
| ✗Sin aumentar el nº de acciones | 291M | 268M |
| ✗Margen bruto al alza | 59.8% | 62.2% |
| ✗Rotación de activos al alza | 0.39 | 0.40 |
| Calidad del negocio | FY25 |
|---|---|
| ✗Margen FCF > 10 % | -19.6% |
| ✗ROCE > 10 % | 6.6% |
| ✓Ventas > 5 %/año (3 años) | 91.8% |
| ✗Deuda neta/EBITDA < 3x | 9.7x |
| ✓Reinversión (I+D + capex) > 3 % de ventas | 42.4% |
Alvotech cotiza a 5.00 USD y tiene una capitalización bursátil de $1.8B. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud